Diabetic macular edema

Related records

Broader conditions (16)

• Cardiovascular disorder
• Diabetic retinopathy
• Disease
• Disease by body system or component
• Disease by developmental or physiological process
• Disorder of orbital region
• Disorder of visual system
• Eye disorder
• Human disease
• Metabolic disease
• Nervous system disorder
• Neurovascular disorder
• Ocular vascular disorder
• Retinal disorder
• Retinal vascular disorder
• Vascular disorder

Trials (536)

• 3 Month Outcome of Ziv-aflibercept for DME
• 30g vs 33g Needle for Intravitreal Injections
• 4D-150 in Patients With Diabetic Macular Edema
• 577nm Micropulse Laser Versus 532nm Subthreshold Laser Photocoagulation for Diabetic Macular Edema
• A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study
• A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
• A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
• A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
• A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
• A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
• A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients
• A Comparison of Islet Cell Transplantation With Medical Therapy for the Treatment of Diabetic Eye Disease
• A Comparison of Standard Laser With Micropulse Laser for the Treatment of Diabetic Macular Oedema.
• A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
• A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema
• A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema
• A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
• A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
• A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema
• A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

Drugs in development (34)

• Abicipar pegol Phase 2
• Aliskiren Phase 2
• Bevacizumab Phase 3
• Bevasiranib Phase 2
• Brolucizumab Phase 3
• Bromfenac Phase 1
• Choline fenofibrate Phase 2
• Cibinetide Phase 1
• Conbercept Phase 3
• Danazol Phase 2
• Dexamethasone Phase 3
• Feniralstat Phase 2
• Fluocinolone acetonide Phase 3
• Mecamylamine Phase 2
• Nepafenac Phase 3
• Nesvacumab Phase 2
• Ocriplasmin Phase 2
• Octreotide Phase 1
• Pegaptanib sodium Phase 2
• Potassium chloride Phase 1

Other linked drugs (7)

• Aflibercept
• Dextromethorphan hydrobromide
• Faricimab
• Infliximab
• Methotrexate
• Minocycline
• Nesvategrast isobutanolammonium